ACTRN12618001502224终止1 期
A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- IQVIA
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A phase I, double-blind, placebo-controlled, ascending single intravenous dose, safety, tolerability, pharmacokinetic and pharmacodynamic study in healthy participants and non-cystic fibrosis bronchiectasis patients colonized with pseudomonas aeruginosa administered INFEX702ISRCTN17978477Infex Therapeutics44
尚未招募
1 期
A Phase I, Randomized, Placebo-Controlled, First in Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of LTSE-2578 in Healthy ParticipantsIdiopathic pulmonary fibrosisACTRN12624000535572hotse Bio, Inc.64
进行中（未招募）
1 期
Study for patients with relapsed, refractory, incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives).relapsed, refractory, incurable teratomaEUCTR2014-000428-12-FRovartis Pharma Services AG90
进行中（未招募）
1 期
Study for patients with relapsed, refractory, incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives).EUCTR2014-000428-12-NLovartis Pharma Services AG42
进行中（未招募）
1 期
Study for patients with relapsed, refractory,incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives)EUCTR2014-000428-12-ITOVARTIS FARMA S.P.A.10